Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : TGL WHAAAAAAAT! Alerts, thoughts, discussion. -- Ignore unavailable to you. Want to Upgrade?

To: Joe Copia who wrote (80183)	2/15/2001 9:10:20 AM
From: Brister	Respond to of 150070

Hello Joe; latest up date on Cryopak up over 125% YTD Cryopak has made good progress this year. Cryopak Industries Posts ►First Quarterly Net Profit and Record Sales for the Quarter Ended December 31, 2000 Feb 13 Blood Systems Inc. Selects Cryopak's Flexible Thermal Blanket for Cold-Chain Protection - Mon Feb 5 CYPKF.OB Cryopak Announces Senior Management Re-Organization - PR Newswire Wed Jan 31 CYPKF.OB GlaxoSmithKline Retains Cryopak for Cold-Chain Management Consulting - PR Newswire Wed Jan 24 CYPKF.OB Cryopak's Northland Custom Packaging Inc. Develops Revolutionary Fertilizer Delivery and Packaging System with Spectrum Pacific for Re-Forestation - Thu Jan 11 CYPKF.OB Cryopak receives major retail purchase from BJ's Wholesale Club stores Tue Dec 19 CYPKF.OB Cryopak's Northland division delivers first shipment to Rubbermaid Home Products Thu Nov 30 CYPKF.OB Cryopak Announces Record First-Half - Sales Up 40.3% - PR Newswire see ya!

To: Joe Copia who wrote (80183)	2/15/2001 9:26:58 AM
From: StocksDATsoar	Respond to of 150070

KAAAAAAAAAAAAAAAAAAAAAAAAAABOOOOOOOOOOOOOOOOOOOOOOOOOOOOOM CYAN : CYANOTECH CORP (NASDAQ) All Headlines Human Clinical Trial Shows Spirulina May Increase Natural Cancer Fighting Substances in the Body KAILUA-KONA, Hawaii, Feb 14, 2001 (BW HealthWire) -- Cyanotech Corporation (Nasdaq NMS: CYAN chart, msgs), the world leader in producing high-value, natural products from microalgae, said today that new research has been reported finding that Spirulina may promote the activation of natural cancer-fighting substances in the body. The human clinical trial was reported by scientists from the Osaka Institute of Public Health in Japan at the 30th Annual Meeting of the Japanese Society for Immunology held in November 2000. The clinical study of volunteers over 40 years of age showed that Spirulina significantly increased the tumor killing ability of Natural Killer Cells and interferon gamma, and continued for 12-24 weeks after stopping the administration of Spirulina. Earlier, in a study reported at the 59th Annual Meeting of the Japanese Cancer Association (October, 2000) the Osaka group also found that the co-administration of Spirulina extract with a bacterial cell wall product significantly increased the regression of implanted tumor cells in mice compared to the administration of the cell wall product alone. More than 80% remission was obtained with this co-treatment. "Although Cyanotech was not involved with or a sponsor of these studies, we believe the results are potentially meaningful and should be more widely communicated to persons interested in Spirulina as a nutritional supplement," said Gerald R. Cysewski, Ph.D., chairman, president and CEO. Cyanotech Corporation, the world's leader in microalgae technology, produces high-value natural products from microalgae, and is the world's largest commercial producer of natural astaxanthin (pronounced "asta-zan-thin") from microalgae. Products include BioAstin(TM) natural astaxanthin, a powerful antioxidant with expanding applications as a human nutraceutical; NatuRose(R) natural astaxanthin for the aquaculture and animal feed industry; Spirulina Pacifica(R), a nutrient-rich dietary supplement; and phycobiliproteins, which are fluorescent pigments used in the immunological diagnostics market. Spirulina and BioAstin are sold directly online through www.nutrex-hawaii.com and through resellers worldwide. Corporate and product information is available at www.cyanotech.com. Contact: Ronald P. Scott EVP-Finance & Administration (808) 326-1353 rscott@cyanotech.com or Bruce Russell Investor Relations (310) 216-1414 brucerussell@ruscom.com